Caremark Rx — Merger or Acquisition (February 2007)
23 slides from Caremark Rx's merger presentation, Feb 2, 2007
Slide 1: The CVS/Caremark Merger is in the Best Interest of Shareholders
1 The CVS/Caremark Merger is in the Best Interest of Shareholders February 2, 2007 Filed by Caremark Rx, Inc. Pursuant to Rule 425 under the Securities Act of 1933 and Deemed Filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Company: Caremark Rx, Inc. Commission File No.:
Slide 2: Forward-looking statements
2 This document contains certain forward-looking statements about Caremark and CVS. When used in this document, the words “anticipates”, “may”, “can”, “believes”, “expects”, “projects”, “intends”, “likely”, “will”, “to be” and any similar expressions and any other statements that are not historical
Slide 3: Important Information
3 CVS has filed with the SEC a registration statement on Form S-4 that was declared effective by the SEC on January 19, 2007. This registration statement includes a joint proxy statement/prospectus in connection with the proposed merger. Caremark and CVS urge investors and stockholders to read the j
Slide 4: Caremark Profile
4 Leading pharmaceutical services company providing comprehensive drug benefit services to health plan sponsors and their participants Uniquely Integrated Services PBM, Specialty, Disease Management Clients Corporate health plans Managed care organizations and insurance companies Unions Government a
Slide 5: Slide 5
Slide 6: Slide 6
Slide 7: Slide 7
Slide 8: Caremark Profile
Caremark retail network includes 60,000 pharmacies nationwide Caremark operations – 7 mail pharmacies – 21 specialty pharmacies – 9 customer call centers – 12 client-site pharmacies – Industry’s only FDA regulated repackaging plant 13,000 employees, including 1,300 pharmacists Headquarters Medical C
Slide 9: CVS Profile
6 Nation’s largest retail pharmacy with more than 6,200 retail and specialty stores in 43 states Services CVS/pharmacy stores CVS.com MinuteClinic PharmaCare (PBM, Mail, Specialty services) 170,000 employees, including 20,000 pharmacists 2006 revenue $43.8 billion 2006 prescriptions filled 495 milli
Slide 10: CVS Profile
7 PharmaCare Specialty Pharmacy Stores #1 or #2 market share in 75% of the top 100 markets in which CVS operates States with CVS/pharmacy Retail Stores 16% Share of U.S. Retail Scripts CVS Profile
Slide 11: CVS/Caremark Merger Overview
8 February 2007 Corporate: Woonsocket, RI PBM: Nashville, TN 50/50 Split Chairman: Mac Crawford President & CEO: Tom Ryan CFO: Dave Rickard President PBM: Howard McLure CVS (NYSE) CVS/Caremark Corporation CVS/Caremark Merger Overview Expected Closing Headquarters Board Composition Management Team Sy
Slide 12: CVS/Caremark Governance Structure Upon Close
9 Provides for annual election of all directors Will have majority voting provision Separate CEO and Chairman Has stock ownership guidelines for D&O Allows stockholders to ratify auditors CVS/Caremark Governance Structure Upon Close
Slide 13: Caremark Board Considered Consumer Strategy Superior to PBM Combination
10 Financial Significance Strategic Significance Consumer Strategy National Retail Chain PBM Caremark Board Considered Consumer Strategy Superior to PBM Combination (Aug 2006) Low Low High High
Slide 14: CVS/Caremark Merger Capitalizes on Evolving Industry Trends
11 CVS/Caremark Merger Benefit Market Trends CVS/Caremark Merger Capitalizes on Evolving Industry Trends In store enrollment and consultation; Medication Therapy Management Medicare Part D More transparency at point of sale - consumer able to make totally informed decisions Cost Shift to Consumer Re
Slide 15: CVS/Caremark Merger Enhances Shareholder Value
12 Uniquely positioned to capitalize on trends and better serve customers Will enable creation of differentiated services More effective cost management for payors More access to information and choice for consumers Received necessary regulatory approvals from FTC and SEC Shareholder votes are last
Slide 16: CVS/Caremark Merger Enhances Shareholder Value
13 Substantial FCF will enable flexibility for investments in existing business, strategic opportunities, dividends and share repurchases Solid investment grade credit rating Proven track-records with large scale acquisition integration History of exceeding stated synergies Visionary leadership Clie
Slide 17: Near-Term Revenue Opportunities Unique to CVS/Caremark Combination
14 Incremental opportunities of $800 M to $1 B in 2008 Half from PBM, half from retail Revenue estimates based on market research and PharmaCare-CVS experience Revenue synergy examples: Improved access/services for PBM specialty participants Retail to mail conversion (including in-store pick up) Fro
Slide 18: Caremark Board Concluded that Express Proposal Not in Best Interests of Shareholders
15 No experience with large-scale merger integration Recent integration track-record questionable Limited capital for investment in existing business, strategic opportunities, dividends and share repurchases ESRX recently placed on negative watch by rating agencies Clients overwhelmingly negative Ri
Slide 19: Express Scripts Proposal Includes Material Conditions
16 A due diligence review Satisfaction of financing conditions Anti-trust and other regulatory approvals Approval by their own shareholders – a process they have not even begun and, which by their own admission, would prevent their illusory February 13 deadline from even occurring No decline in the
Slide 20: Value of Transactions for Caremark Shareholders
17 * VALUES DO NOT REFLECT CONDITIONALITY AND BUSINESS RISK FACTORS ASSOCIATED WITH ESRX PROPOSAL Value of Value of Calculated as of 1/31/2007 CVS Merger ESRX Proposal Counterparty Stock Price 33.65 $ 69.52 $ Exchange Ratio 1.67 0.426 Implied Value of Stock Consideration 56.20 $ 29.62 $ Value of Div
Slide 21: Responses to Express Scripts arguments
18 Not appropriate comparisons-natural conflicts with former Pharma owners, Rite Aid had serious accounting issues CVS/CMX addresses evolving marketplace needs “Vertical PBM transactions have failed to create stockholder value” 3 into 2 mergers face significant antitrust obstacles/delays Heavy large
Slide 22: CVS/Caremark Merger is in the Best Interests of Shareholders
19 • Immediate and concrete financial benefits • February 2007 close • Significant strategic benefits • Clients supportive • Proven management teams • Highly conditional offer • Financial benefits suspect • Uncertain timing • Lacks strategic rationale • Client attrition • CMX would be 20x the larges
Slide 23: The CVS/Caremark Merger is in the Best Interest of Shareholders
20 The CVS/Caremark Merger is in the Best Interest of Shareholders February 2, 2007